Product Information
DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.8569 per EA under NDC 00378026691. Its NADAC has been published 65 times since Apr 2, 2025.
The Low Outlier badge above means this manufacturer's average price in the Dabigatran Etexilate market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
150 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378026691
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208067On Market Since
2/25/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 65 times since Apr 2, 2025, and over the history we have for it it has declined 48.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8569 per EA |
|---|---|
| All-time high | $1.6485 (Apr 16, 2025) |
| All-time low | $0.8446 (Feb 18, 2026) |
| 52-week high | $1.4231 |
| 52-week low | $0.8446 |
| Median price | $1.0897 |
| Average price | $1.1364 |
| Largest weekly change | -9.3% (Sep 17, 2025) |
| Weeks tracked | 65 |
| Tracking since | Apr 2, 2025 |
Generic Alternatives
The matcher finds 4 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 4 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 150 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 150 MG CP, manufactured by Mylan Pharmaceuticals Inc., is $0.8569 per EA (NDC 00378026691), effective Jun 24, 2026.
How has the price of DABIGATRAN ETEXILATE 150 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has declined 48.0%. It has been tracked across 65 weekly CMS publications since Apr 2, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 150 MG CP?
Since Apr 2, 2025, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has ranged from a low of $0.8446 (Feb 18, 2026) to a high of $1.6485 (Apr 16, 2025), with a median of $1.0897 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 150 MG CP?
4 NADAC-published products share the same active ingredient, strength, and dosage form as DABIGATRAN ETEXILATE 150 MG CP, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 150 MG CP?
DABIGATRAN ETEXILATE 150 MG CP (NDC 00378026691) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification